Transactions
1
Insider / Edwards Lifesciences Corp
Davis Leslie C.
Director at Edwards Lifesciences Corp
- Company
- Edwards Lifesciences Corp
- Ticker
- EW
- First filing on record
- May 8, 2026
- Latest trade on record
- May 8, 2026
- SEC filings
- EDGAR ↗
Davis Leslie C., Director at Edwards Lifesciences Corp, has disclosed 1 transaction in EW since May 8, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed May 8, 2026, 0 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
0.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Davis Leslie C. reported 1 transaction that was neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 1 | 3,251 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| EW | Other A | May 8, 2026 | May 8, 2026 | 0d | 3,251 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Form 4 | 0001225208-26-005046 | 1 | published | EDGAR ↗ |
Other insiders at Edwards Lifesciences Corp
- Lippis Daniel J. CVP, JAPAC 52 rows
- Zovighian Bernard J CEO 35 rows
- Ullem Scott B. Director 31 rows
- BOBO DONALD E JR CVP,Strategy/Corp Development 30 rows
- Mistras Theodora Chief Financial Officer 23 rows
- Chopra Daveen CVP, TMTT & Surgical 16 rows
- Markowitz Wayne CVP, JAPAC 14 rows
- Dahl Andrew M. SVP, Corporate Controller 9 rows
- Bruls Annette CVP, EMEACLA 6 rows
- Feinberg David T Director 5 rows
Everyone on file, with contracts and lobbying under the company's name: Edwards Lifesciences Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | May 8, 2026 | May 8, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.